Implant Sciences Corp.
This article was originally published in The Gray Sheet
Executive Summary
Receives license to manufacture and distribute the I-Plant Iodine-125 brachytherapy seeds from the Radiation Control Program of the Commonwealth of Massachusetts' Department of Public Health, administrator for the Nuclear Regulatory Commission's oversight of radioactive source manufacture, the company announces Jan. 12. Implant Sciences received FDA 510(k) clearance for the seeds in May for the treatment of prostate cancer